ACC 2019 – Low risk of patients being denied transcatheter aortic valves
The battle for dominance of the transcatheter aortic valve market has shifted to new territory. And once again, Edwards Lifesciences is winning.
Deals galore for a new generation of transcatheter mitral valves
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
Boston and Edwards make a smart judgement
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
The fourth quarter sell-off hurt big medtech less than big pharma
Some medtech stocks did decline in 2018, but many more increased in value.
Medtech news over the Christmas period
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.
Roche leaves Abbott in the dust when it comes to US approval times
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Portico has its foot in the door, but various trials await
Abbott Laboratories has posted decent results for its transcatheter aortic valve, but all-important US pivotal data are in the offing.
Jenavalve set on US approval, but faces a fight for market share
Smaller transcatheter aortic valve groups face a tricky future.
Medtechs prioritise efficiency when it comes to hiring
Big cap medtech is hiring, largely thanks to organic growth.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.